Savara aPAP ClearPath Dried Blood Spot test

Biopharmaceutical firm Savara has launched the aPAP ClearPath Dried Blood Spot test in the US to help diagnose aPAP, a rare autoimmune lung disease resulting from antibodies targeting Granulocyte-macrophage colony-stimulating factor (GM-CSF). Savara developed and validated the test with diagnostics firm TrilliumBio. The DBS test shows a high correlation between GM-CSF autoantibody levels in dried serum and traditional serum samples, Savara said, and has achieved 100 percent analytical sensitivity and specificity in a cohort of individuals with confirmed GM-CSF autoantibody status.